Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303

1.

Effectiveness of lamotrigine in bipolar disorder in a clinical setting.

Ketter TA, Brooks JO, Hoblyn JC, Champion LM, Nam JY, Culver JL, Marsh WK, Bonner JC.

J Psychiatr Res. 2008 Nov;43(1):13-23. doi: 10.1016/j.jpsychires.2008.02.007.

PMID:
18423667
2.

The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial.

Ketter TA, Greist JH, Graham JA, Roberts JN, Thompson TR, Nanry KP.

J Clin Psychiatry. 2006 Mar;67(3):400-6.

PMID:
16649826
3.

Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients.

Ittasakul P, Johnson KR, Srivastava S, Childers ME, Brooks JO 3rd, Hoblyn JC, Ketter TA.

J Affect Disord. 2012 Mar;137(1-3):139-45. doi: 10.1016/j.jad.2011.12.024. Epub 2012 Jan 10.

PMID:
22240084
4.

Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression.

Ahn YM, Nam JY, Culver JL, Marsh WK, Bonner JC, Ketter TA.

Ann Clin Psychiatry. 2011 Feb;23(1):17-24.

PMID:
21318192
5.

Lamotrigine in patients with bipolar disorder and cocaine dependence.

Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla L.

J Clin Psychiatry. 2003 Feb;64(2):197-201.

PMID:
12633129
6.

Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash.

Ketter TA, Wang PW, Chandler RA, Alarcon AM, Becker OV, Nowakowska C, O'Keeffe CM, Schumacher MR.

J Clin Psychiatry. 2005 May;66(5):642-5.

PMID:
15889953
7.

Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.

van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, Nolen WA; LamLit Study Group.

J Clin Psychiatry. 2009 Feb;70(2):223-31. Epub 2008 Dec 30.

PMID:
19200421
8.

Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study.

Altamura AC, Mundo E, Dell'Osso B, Tacchini G, Buoli M, Calabrese JR.

J Affect Disord. 2008 Sep;110(1-2):135-41. doi: 10.1016/j.jad.2008.01.017. Epub 2008 Mar 10.

PMID:
18329720
9.

A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder.

Biederman J, Joshi G, Mick E, Doyle R, Georgiopoulos A, Hammerness P, Kotarski M, Williams C, Wozniak J.

CNS Neurosci Ther. 2010 Apr;16(2):91-102. doi: 10.1111/j.1755-5949.2009.00121.x.

PMID:
20415838
10.

Adjunctive aripiprazole in treatment-resistant bipolar depression.

Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM.

Ann Clin Psychiatry. 2006 Jul-Sep;18(3):169-72.

PMID:
16923655
11.

Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder.

Khan A, Ginsberg LD, Asnis GM, Goodwin FK, Davis KH, Krishnan AA, Adams BE.

J Clin Psychiatry. 2004 Nov;65(11):1483-90.

PMID:
15554760
12.

Lamotrigine in rapid-cycling bipolar disorder.

Fatemi SH, Rapport DJ, Calabrese JR, Thuras P.

J Clin Psychiatry. 1997 Dec;58(12):522-7.

PMID:
9448654
13.

Open-label, concomitant use of lamotrigine and other medications for bipolar disorder.

Bowden CL, Edwards S, Evoniuk G.

CNS Spectr. 2008 Jan;13(1):75-83.

PMID:
18204417
14.

Clinical factors leading to lamotrigine prescription in bipolar outpatients: subanalysis of the SIN-DEPRES study.

Grande I, Balanzá-Martínez V, Jiménez-Arriero M, Iglesias Lorenzo FG, Franch Valverde JI, de Arce R, Zaragoza S, Cobaleda S, Vieta E; SIN-DEPRES Group.

J Affect Disord. 2012 Dec 20;143(1-3):102-8. doi: 10.1016/j.jad.2012.05.035. Epub 2012 Jul 28.

PMID:
22842026
15.

Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers.

Chang JS, Moon E, Cha B, Ha K.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1322-6. doi: 10.1016/j.pnpbp.2010.07.020. Epub 2010 Jul 29.

PMID:
20673782
16.

Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.

Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS.

Am J Psychiatry. 2006 Feb;163(2):210-6.

PMID:
16449473
17.

A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression.

McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, Ascher J.

J Clin Psychiatry. 2004 Feb;65(2):204-10.

PMID:
15003074
18.

Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD.

Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E, Nierenberg AA, Calabrese JR, Sachs GS, Pollack MH; STEP-BD Investigators.

J Clin Psychopharmacol. 2004 Oct;24(5):512-20.

PMID:
15349007
19.

An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression.

Chang K, Saxena K, Howe M.

J Am Acad Child Adolesc Psychiatry. 2006 Mar;45(3):298-304.

PMID:
16540814
20.

Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD.

Marangell LB, Martinez JM, Ketter TA, Bowden CL, Goldberg JF, Calabrese JR, Miyahara S, Miklowitz DJ, Sachs GS, Thase ME; STEP-BD Investigators.

Bipolar Disord. 2004 Apr;6(2):139-43.

PMID:
15005752

Supplemental Content

Support Center